Kintor Pharmaceutical Limited
KNTPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $0 | $0 | $34 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $10 | $42 | $3 | $0 |
| Gross Profit | -$5 | -$42 | -$3 | $34 |
| % Margin | -94.6% | – | – | 100% |
| R&D Expenses | $78 | $939 | $828 | $1 |
| G&A Expenses | $62 | $28 | $43 | $45 |
| SG&A Expenses | $88 | $35 | $64 | $60 |
| Sales & Mktg Exp. | $27 | $7 | $20 | $15 |
| Other Operating Expenses | -$27 | $43 | -$749 | $813 |
| Operating Expenses | $140 | $1,017 | $143 | $874 |
| Operating Income | -$145 | -$152 | -$945 | -$840 |
| % Margin | -2,891.4% | – | – | -2,452.8% |
| Other Income/Exp. Net | -$11 | $1 | -$9 | -$2 |
| Pre-Tax Income | -$155 | -$151 | -$953 | -$842 |
| Tax Expense | $0 | -$8 | $1 | $0 |
| Net Income | -$155 | -$1,061 | -$954 | -$842 |
| % Margin | -3,105.8% | – | – | -2,460% |
| EPS | -0.36 | -2.47 | -2.53 | -2.36 |
| % Growth | 85.4% | 2.4% | -7.2% | – |
| EPS Diluted | -0.36 | -2.47 | -2.53 | -2.36 |
| Weighted Avg Shares Out | 431 | 429 | 377 | 0 |
| Weighted Avg Shares Out Dil | 431 | 429 | 377 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $13 | $7 | $12 |
| Interest Expense | $9 | $10 | $8 | $2 |
| Depreciation & Amortization | $18 | $14 | $13 | $11 |
| EBITDA | -$128 | -$1,056 | -$956 | -$828 |
| % Margin | -2,567.4% | – | – | -2,418.8% |